VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a leading provider of compliant digital health infrastructure and on-demand healthcare services across the United States, is pleased to provide an update on the Company’s recent operational performance and platform activity.

Operational Highlights

• Exceeded 1.3 million in product orders placed ahead of schedule, surpassing our full-year 2025 guidance
• Order volume was driven primarily by an initial base of approximately 400 licenses that were onboarded and activated during the year
• The platform now has approximately 2,500 licenses, surpassing the Company’s full-year 2025 target of 1,000, with the majority still in onboarding or early activation stages
• Actively advancing VSDHOne 2.0 bringing enhanced platform capabilities, partner workflows, and scalability as additional licenses are activated

Operational Scale and Platform Momentum

VSDHOne, Hydreight’s enterprise-focused vertical, began meaningful commercial activity in late June 2025 and has since been progressively scaled as part of the Company’s broader platform strategy.

The Company is pleased to announce that it has exceeded 1.3 million Product Orders Placed, surpassing its previously stated full-year 2025 operational target ahead of year-end. Hydreight had guided to approximately 1.3 million Product Orders Placed for 2025, and achieving this milestone early reflects continued platform adoption, increasing partner demand, and disciplined execution. Orders placed in recent weeks are expected to be fulfilled and delivered in accordance with normal fulfillment timelines.

Hydreight has historically used Product Orders Placed as its primary operational metric, as it reflects demand initiated by licenses and provides the clearest indicator of real-time platform activity. While some accounting models reference orders delivered, timing between each stage may vary and certain orders may be cancelled or returned, with all measures reconciling at period-end through the Company’s financial reporting. The Company will continue using Product Orders Placed as its primary operational KPI.

The Company achieved this milestone primarily through its initial base of approximately 400 licenses that were fully onboarded and activated during the year, with incremental contributions from newer platform offerings that remain in the early stages of scale.

Hydreight has continued to expand its ecosystem and now supports approximately 2,500 licenses, exceeding its previously stated full-year 2025 target of 1,000. While a portion of these licenses are fully active, the majority remain in onboarding or early activation stages and are not yet contributing materially to order volume. Management expects utilization to scale progressively as onboarding is completed, positioning the Company for increased platform activity as it enters 2026.

“Crossing 1.3 million product orders placed is a meaningful validation of the demand we’re seeing across our platform and the discipline with which we’ve scaled,” said Shane Madden, Chief Executive Officer of Hydreight. “What’s particularly encouraging is that this order volume was generated before the majority of our newer licenses were fully onboarded and scaled. Throughout 2025, we focused on building the foundation — including technology, pharmacy capacity, clinical coverage, and governance — so the platform can support significantly greater scale as we move forward.”

Average Order Value and Long-Term Value Creation

As previously discussed with investors, average order value (AOV) across the platform reflects the early-stage scaling of newer offerings, including the Company’s VSDHOne enterprise vertical. As Hydreight expands across additional use cases and partner models, management remains focused on long-term value creation, balancing order volume, product mix, and recurring patient engagement rather than optimizing for single-order economics in isolation.

“We’re focused on building a business designed for durability and scale,” said Shane Madden, Chief Executive Officer of Hydreight. “As newer verticals mature and licenses fully activate, we expect platform metrics to evolve naturally, but our priority remains disciplined execution and long-term value creation.”

A Milestone Year for Hydreight

2025 marked a defining year for Hydreight as the Company continued to scale its national digital health infrastructure, enabling healthcare brands, clinics, and enterprises to operate compliantly across all 50 U.S. states through a unified technology, clinical, pharmacy, and regulatory framework.

Throughout the year, the Company focused on:

• Expanding high-volume platform partners
  
• Increasing utilization across multiple healthcare categories
  
• Scaling pharmacy throughput and operational capacity
  
• Strengthening institutional-grade compliance, reporting, and governance
• Advancing vertical integration to improve pharmacy margins, enhance supply chain reliability, and strengthen the long-term defensibility of the platform

Surpassing the Company’s stated 2025 operational targets reinforces management’s confidence in Hydreight’s long-term strategy and execution.

2026 Guidance Update

The Company previously indicated that it intended to provide initial commentary on 2026 expectations in mid-December. Given the pace of execution and several initiatives currently under internal evaluation — including enterprise partnerships, M&A initiatives, and other strategic considerations — Hydreight believes it is prudent to provide formal 2026 guidance early in the new year, once there is greater accuracy and visibility.

In addition, the Company is currently reviewing a pipeline of late-stage opportunities spanning Q4 2025 and Q1 2026, including enterprise customer opportunities that are progressing through clinical validation, treatment planning, and operational readiness reviews by Hydreight’s medical and pharmacy teams. Management believes incorporating these developments into future guidance will provide a more complete and accurate view of the business.

“As we look ahead, we remain focused on executing the core business while carefully evaluating a number of strategic initiatives,” said Shane Madden, Chief Executive Officer of Hydreight. “We believe it’s important to provide guidance once there is sufficient visibility and certainty, rather than prematurely, so investors have a clear and complete picture of the business as it enters its next phase of growth.”

Further updates will be provided in the new year through news releases and investor communications.

Looking Ahead

As Hydreight closes out 2025 having exceeded its primary operational milestone, the Company enters 2026 with increased scale, deeper platform penetration, and a continued focus on disciplined execution across its digital health platform.

The Company thanks its partners, healthcare professionals, licensees, and shareholders for their continued support.

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Contact
Email: ir@hydreight.com; Telephone: (702) 970-8112

Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 300 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne - Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Use of Non-GAAP Financial Measures:
This release contains references to non-GAAP financial measures Adjusted Revenue, Adjusted Gross Margin and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as GAAP gross margin plus inventory impairment plus the deferred portion of business partner contract revenue. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and (ii) share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance. The Company believes that the measures provide information useful to its shareholders and investors in understanding the Company’s operating cash flow growth, user growth, and cash generating potential and may assist in the evaluation of the Company’s business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding expectations for the 2025 and 2026 strategic outlook, the Company’s growth, margins, and VSDHOne’s and Hydreight’s anticipated performance and related operational metrics. This also includes information regarding Product Orders, which are defined as follows: Product Orders Placed reflect demand initiated by licensees and partners; Product Orders Fulfilled refer to orders processed by pharmacy partners and prepared for delivery; and Product Orders Delivered refer to orders that have reached the patient. Orders may be cancelled or returned, which can affect the relationship between orders placed, fulfilled, delivered, and recognized revenue. Hydreight uses Product Orders Placed as its primary operational KPI because it reflects real-time platform activity and partner demand. All operational and accounting measures reconcile at period end.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Regulatory Statements
Neither the TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this communication.

This communication does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption.